Medtronic plcMDT
Medtronic plc Financial Overview 2022–2026
Updated Jul 10, 2026Medtronic finalized the initial public offering of its Diabetes unit in FY2026 precisely as the segment delivered a standout 13% revenue surge to $3.1 billion. This strategic separation defines the core investment thesis: the medical technology giant is actively shedding peripheral lines to focus operational capital on its largest, most dominant device franchises.
Despite early supply chain disruptions, total revenue grew from $31.7 billion in FY2022 to $36.4 billion in FY2026. This top-line expansion was heavily anchored by the Cardiovascular portfolio, which posted a 12% net sales increase to reach $14.0 billion in FY2026 behind strong adoption of transcatheter aortic valve replacements and pacing systems. The company maintained strict cash discipline throughout this structural transition. Medtronic consistently generated deep liquidity, securing $5.4 billion in free cash flow in FY2026 following a massive $3.2 billion deployment for share repurchases during FY2025.
The market carefully weighed these portfolio adjustments against rising tariff and restructuring costs. At the close of FY2026, the stock traded at 22.3x earnings at $83.32 per share. This translated to a $106.7 billion market cap, slightly contracting from the 23.3x multiple and $107.9 billion valuation the company commanded at the end of FY2025.
Recent Developments (Q3 and Q4 2026)
Medtronic accelerated top-line growth in Q3 2026, driving a 9% net sales increase to $9.0 billion. Earnings pressure persisted as Q3 2026 diluted EPS dropped to $0.89 from $1.01 year-over-year due to tariff duties and asset write-offs. To bolster its coronary portfolio, the company advanced an acquisition of CathWorks Ltd. for up to $585 million. In Q4 2026, Medtronic secured early FDA clearance for its MiniMed Flex insulin pump, triggering a $157 million development charge that reduced quarterly EPS by $0.08.
Leadership changes also took hold, with Dr. Kweli Thompson replacing Brett Wall as head of the $10.3 billion Neuroscience portfolio effective June 1, 2026. Bulls argue that early MiniMed Flex commercialization and targeted acquisitions will accelerate future expansion. Bears warn that recurring write-offs, an April 2026 IT system breach, and downwardly revised FY2026 non-GAAP EPS guidance of $5.50 to $5.54 reflect ongoing operational friction. Shares traded at 21.3x earnings as of June 18, 2026.
What to watch: MiniMed Flex commercial launch metrics; remediation costs from the April 2026 cybersecurity breach.
Rev
$36.36B
FY2026
NI
$4.84B
FY2026
EPS
$3.75
FY2026
OCF
$7.33B
FY2026
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
Medtronic plc 8-K Report, Financial Results (Jun 3, 2026)
Medtronic plc (MDT) has filed an 8-K report on June 3, 2026, to announce its financial results for the fourth quarter and the full fiscal year 2026. The report primarily serves to furnish the earnings press release associated with these results. Investors should refer to Exhibit 99.1 for the detailed financial performance, including revenue, profitability, and segment-specific performance for the period. This filing is crucial for understanding Medtronic's recent operational and financial standing and for making informed investment decisions. While the 8-K itself is a procedural filing to report the release of financial information, the attached press release will contain the substantive data investors need. This typically includes key financial metrics, management commentary on performance drivers and outlook, and potentially updates on strategic initiatives or product developments. Investors are encouraged to review the full press release to grasp the complete picture of Medtronic's fiscal year 2026 performance and its trajectory moving forward.
Medtronic plc 8-K Report, Executive Changes (May 18, 2026)
Medtronic plc (MDT) has filed an 8-K report on May 18, 2026, to announce a significant leadership transition within its Neuroscience Portfolio. Brett Wall is departing from his role as Executive Vice President and President, Neuroscience Portfolio. While he will remain with the company until September 1, 2026, to ensure a smooth handover, his departure marks a change in leadership for this key division. Dr. Kweli Thompson, currently Senior Vice President and President of Cardiac Rhythm Management, will assume the leadership of the Neuroscience Portfolio starting June 1, 2026. Investors should monitor the performance and strategic direction of the Neuroscience Portfolio under Dr. Thompson's leadership.
Medtronic plc 8-K Report, Regulation FD Disclosure (Apr 27, 2026)
Medtronic plc (MDT) has disclosed a data security incident where an unauthorized third party accessed certain IT systems. The company identified the breach, took immediate containment measures, and engaged external cybersecurity experts to investigate. Based on the current investigation, Medtronic has not found any impact on its products, patient safety, customer relationships, manufacturing, distribution, or financial reporting. The company currently anticipates no material impact on its business or financial results from this incident. Investors should note that Medtronic has provided a statement on its website regarding this event, which is furnished as part of this 8-K filing. While the company has taken prompt action and currently assesses the impact as immaterial, ongoing monitoring and the full scope of the investigation will be crucial to watch for any potential future developments. The forward-looking statements disclaimer highlights inherent risks and uncertainties associated with such events.
Medtronic plc 8-K Report, Regulation FD Disclosure (Mar 24, 2026)
Medtronic plc (MDT) announced an important regulatory milestone for its consolidated subsidiary, MiniMed Group, Inc. The U.S. Food and Drug Administration (FDA) has granted clearance for the MiniMed Flex™, a next-generation insulin pump. This clearance arrived several months ahead of schedule, enabling an earlier commercial launch for this significant product in the diabetes management market. The development of the MiniMed Flex was partially funded by Blackstone, and under their agreement, Medtronic will incur a one-time charge of $157 million in the fourth quarter of fiscal year 2026, impacting reported EPS by approximately $0.08 per share. This charge relates to future payments to Blackstone based on sales performance during the initial two years post-launch. Additionally, the previously disclosed initial public offering (IPO) of 10% of MiniMed will contribute an additional $0.04 per share dilution to Medtronic shareholders in the fourth quarter of fiscal year 2026. Consequently, Medtronic has revised its non-GAAP EPS guidance for fiscal year 2026 downward to a range of $5.50 to $5.54, from the previous $5.62 to $5.66 range. The company's long-term outlook for fiscal year 2027, projecting high single-digit EPS growth, remains unchanged.
Medtronic plc 8-K Report, Financial Results (Feb 17, 2026)
Medtronic plc (MDT) has filed an 8-K report on February 17, 2026, to announce its third quarter fiscal year 2026 financial results. The primary purpose of this filing is to furnish the press release detailing these results, which were released on the same day. Investors should review the press release (Exhibit 99.1) for specific performance metrics, revenue figures, profitability, and any forward-looking statements or guidance provided by the company for the remainder of the fiscal year. This report serves as the official notification of the company's recent financial performance. While the 8-K itself is brief, it directs investors to the comprehensive financial data contained within the furnished press release. Key areas of interest for investors will likely include the performance of Medtronic's various business segments, comparisons to analyst expectations, and any commentary on the macroeconomic or industry-specific factors impacting the results. Understanding these details is crucial for assessing Medtronic's current financial health and future prospects.
View all 8-K filings →